1253 Results

People

  1. Motzer
    Motzer
  2. Kingham
    Kingham
  3. Hudis
    Hudis
  4. Abou-Alfa
    Abou-Alfa
  5. Horwitz
    Horwitz
  6. Zelenetz
    Zelenetz
  7. Kris
    Kris
  8. Perales
    Perales
  9. Aghajanian
    Aghajanian
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (680)
  2. Solid Tumor Oncology Division (431)
  3. Hematologic Malignancies, Division of (230)
  4. Surgery (201)
  5. Center for Hematologic Malignancies (186)
  6. Survivorship Research (182)
  7. Population Sciences Research Program (170)
  8. Epidemiology and Biostatistics (122)
  9. Center for Pancreatic Cancer Research (110)
  10. Genitourinary Oncology Service (109)
  1. "multicenter study"
Formats
  1. Journal Article (1219)
  2. Research Letter (12)
  3. Conference Paper (7)
  4. Correspondence (6)
  5. Review (5)
  6. Guidelines (2)
  7. Editorial (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (680)
  2. Solid Tumor Oncology Division (431)
  3. Hematologic Malignancies, Division of (230)
  4. Surgery (201)
  5. Center for Hematologic Malignancies (186)
  6. Survivorship Research (182)

More Groups

People
  1. Robert Motzer (47)
  2. T Peter Kingham (31)
  3. Clifford Hudis (19)
  4. Andrew Zelenetz (18)
  5. Ghassan Abou-Alfa (18)
  6. Steven Horwitz (18)

More People

Years
  1. 2025 (86)
  2. 2024 (191)
  3. 2023 (130)
  4. 2022 (83)
  5. 2021 (50)
  6. 2020 (63)

More Years

Publications
  1. Journal of Clinical Oncology (118)
  2. Lancet Oncology (57)
  3. New England Journal of Medicine (56)
  4. Clinical Cancer Research (46)
  5. Blood (44)
  6. Cancer (36)

More Publications

Publishers
  1. Elsevier Inc. (152)
  2. Elsevier Science, Inc. (137)
  3. American Society of Clinical Oncology (124)
  4. Springer (84)
  5. Oxford University Press (79)
  6. Wiley Blackwell (71)

More Publishers

Results (1253)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies
    Journal Article

    Shah, N.; Perales, M. A.; Turtle, C. J.; Cairo, M. S.; Cowan, A. J.; Saeed, H.; Budde, L. E.; Tan, A.; Lee, Z.; Kai, K.; more...
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study
    Journal Article

    Berdeja, J. G.; Madduri, D.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; Lesokhin, A.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study
    Journal Article

    Naing, A.; Thistlethwaite, F.; de Vries, E. G. E.; Eskens, F. A. L. M.; Uboha, N.; Ott, P. A.; LoRusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Primary and biomarker analyses of a phase II study
    Journal Article

    D'Angelo, S. P.; Lebbé, C.; Mortier, L.; Brohl, A. S.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G. J.; Hassel, J. C.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): A first-in-human, dose-finding study
    Journal Article

    Sanborn, R. E.; Hamid, O.; de Vries, E. G. E.; Ott, P. A.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; Autio, K. A.; Cho, D. C.; Plummer, R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
    Journal Article

    Advani, R. H.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Christian, B. A.; Ansell, S. M.; Moskowitz, C. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantitative imaging metrics derived from magnetic resonance fingerprinting using ISMRM/NIST MRI system phantom: An international multicenter repeatability and reproducibility study
    Journal Article

    Shridhar Konar, A.; Qian, E.; Geethanath, S.; Buonincontri, G.; Obuchowski, N. A.; Fung, M.; Gomez, P.; Schulte, R.; Cencini, M.; Tosetti, M.; more...
    Medical Physics (2021)

    Fulltext@MSK | Save
  • Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma
    Journal Article

    Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; Park, S. H.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study
    Journal Article

    Pires da Silva, I.; Ahmed, T.; Reijers, I. L. M.; Weppler, A. M.; Betof Warner, A.; Patrinely, J. R.; Serra-Bellver, P.; Allayous, C.; Mangana, J.; Nguyen, K.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save